Navigation Links
PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
Date:6/26/2008

HUNDREDS OF CUSTOMER HOSPITALS USING ELECTRONIC 222 TO ORDER CLASS II

CONTROLLED SUBSTANCES

SEATTLE, June 9 /PRNewswire/ -- PharMEDium Services, LLC, the leading provider of outsourced hospital pharmacy I.V. compounded solutions, has expanded its first-in-the-industry electronic 222 (e-222) ordering initiative, which enables virtually real-time ordering of Schedule II Controlled Substances versus the more time-consuming traditional process, to all hospitals nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051202/PHARMEDIUMLOGO)

The company announced the initiative at the American Society of Health-System Pharmacists' Summer Meeting and exhibition here.

Hundreds of customers are now ordering pain management medications through PharMEDium's e-222 system, which applies to the entire line of its pain management services. "Our expansion of e-222 represents an ongoing commitment to patient safety, quality, and superior customer service. The early and fast adoption by our customers represents their partnership with us in helping make e-222 a standard practice across our industry," said David Jonas, PharMEDium's Chairman and Chief Executive Officer.

PharMEDium's new controlled substance ordering system aligns with the efforts of the U.S. Drug Enforcement Administration (DEA) and drug industry leaders to take advantage of e-commerce tools to improve efficiency and effectiveness associated with controlled substances ordering. DEA requires a Form 222 for all orders of Schedule II Controlled Substances, which until recently could only be processed through paper forms. E-222 ordering takes about 20 seconds, versus about 20 minutes for paper orders, according to DEA's Office of Diversion Control (ODC). In addition, the elimination of the paper Form 222 reduces the time it takes to receive an order by one to two days.
'/>"/>

SOURCE PharMEDium Services, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. March of Dimes announces Prematurity Campaign expansion at Surgeon Generals conference
2. TAU announces new supercenter for renewable energy
3. Ecological Society of America announces its 93rd Annual Meeting
4. Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems
5. BIO-key(R) Announces First Quarter 2008 Earnings Release and Conference Call Schedule
6. Autism Speaks announces multinational initiative
7. Aware Announces Q1 2008 Earnings Conference Call
8. The Alliance for Lupus Research announces 2008 grantees
9. Titanium Group Announces Contract for Security Solution in High-End Residentials
10. National Lung Cancer Partnership announces winner of 2007 Career Development Award
11. BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Institute have identified a molecular interaction that triggers a ... attacking this target with selective drugs might improve treatment. ... a team led by Qunyan Yu, MD, and Peter ... of a certain mutated oncogene and the newly described ...
... all-important channels that control the flow of information in and ... for the split to come when a cell divides. Now, ... Biological Studies watched as new funnel-like pore structures formed from ... This discovery adds to the picture of how a cell ...
... a gene previously linked to impulsive violence appears ... memory and thinking in humans, researchers at the ... Mental Health (NIMH) have found. Brain scans revealed ... to have relatively smaller emotion-related brain structures, a ...
Cached Biology News:New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3Researchers solve mystery of how nuclear pores duplicate before cell division 2Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... reached a definitive agreement with Novartis Pharma AG to ... currently in Phase 3 development.  This agreement is conditional on ... PLC (GSK) on April 22, 2014, which are expected to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... PRINCETON, N.J., Dec. 8 BioWa, Inc., announced today ... its POTELLIGENT(R) Technology for,use in developing and commercializing select ... "GSK is recognized ... drug,discovery," said Dr. Masamichi Koike, BioWa President and CEO. ...
... Dec. 7 Data on Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will ... Francisco. The talk will be presented by Dr Thomas Bumm ... CYT387 in an in- vivo model of myeloproliferative disorders. , ... Effects of CYT387, a Potent Novel JAK2 Inhibitor on ...
... Dynamic Alert,Limited (OTC Bulletin Board: DYMC) is pleased ... markets for its pharmaceutical product line-up. The,modalities will ... rapid onset,through oromucosal absorption, topical applications, such as ... Some products will have,specific uses, while others may ...
Cached Biology Technology:BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3
... of Japan, also named Sendai virus) Envelope ... of molecules by means of membrane fusion. ... Protein, Oligo, cDNA, Antibodies, Vector, and Biomolecule ... EX has a high fusing capability in ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Biology Products: